PBYI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBYI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-03-29), Puma Biotechnology's share price is $5.31. Puma Biotechnology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.57. Hence, Puma Biotechnology's Price-to-Operating-Cash-Flow Ratio for today is 9.38.
The historical rank and industry rank for Puma Biotechnology's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 13 years, Puma Biotechnology's highest Price-to-Operating-Cash-Flow Ratio was 875.71. The lowest was 3.92. And the median was 12.80.
Puma Biotechnology's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.22. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.57.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 205.10% per year.
During the past 13 years, Puma Biotechnology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 205.10% per year. The lowest was -1142.50% per year. And the median was -33.40% per year.
The historical data trend for Puma Biotechnology's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Puma Biotechnology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Price-to-Operating-Cash-Flow falls into.
Puma Biotechnology's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 5.31 | / | 0.566 | |
= | 9.38 |
Puma Biotechnology's Share Price of today is $5.31.
Puma Biotechnology's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.57.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Puma Biotechnology's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan H Auerbach | director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY | 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024 |
Alvin F Wong | officer: Chief Scientific Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Maximo F Nougues | officer: Chief Financial Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Jeffrey Jerome Ludwig | officer: Chief Commercial Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Douglas M Hunt | officer: See Remarks | C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Michael Patrick Miller | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2 |
Adrian Senderowicz | director | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Troy Edward Wilson | director | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Allison Dorval | director | C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821 |
Brian M Stuglik | director | C/O VERASTEM, INC., 117, NEEDHAM MA 02494 |
Jay M Moyes | director | |
Alessandra Cesano | director | 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065 |
Ann Calby Miller | director | C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
Richard Paul Bryce | officer: SR VP, CLINICAL RESEARCH & DEV | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Hugh O'dowd | director | C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139 |
From GuruFocus
By Business Wire 10-20-2022
By Business Wire 06-04-2023
By Business Wire 01-12-2023
By Business Wire 10-27-2022
By Business Wire 12-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.